Preferred Label : Anti-IGSF8 Monoclonal Antibody GV20-0251;
NCIt definition : A human, Fc-attenuated immunoglobulin G1 (IgG1) monoclonal antibody targeting the
immune checkpoint immunoglobulin superfamily member 8 (IGSF8; PGRL; PG regulatory-like
protein, KCT-4, CD81 partner 3; LIR-D1; KASP; KAI/CD82 associated protein; EWI-2;
Glu-Trp-Ile EWI motif-containing protein 2), with potential immune checkpoint inhibitory,
immunostimulating and antineoplastic activities. Upon administration, anti-IGSF8 monoclonal
antibody GV20-0251 targets and binds to IGSF8 expressed on various immune cells, thereby
preventing the binding of IGSF8 to beta 1 integrins and various tetraspanins. This
inhibits IGSF8-mediated signaling and abrogates the IGSF8-mediated inhibition on immune
activation. This may stimulate a T-cell-mediated immune response against cancer cells.
IGSF8, a transmembrane adhesion protein and member of the Ig super family (IgSF),
is an immune inhibitory receptor that plays a key role in cancer cell motility and
suppression of T-cell proliferation and activation. It is involved in tumor cell immune
evasion and the inhibition of immune responses.;
Molecule name : XBH-25; GV20 0251; XBH 25; GV20-0251;
NCI Metathesaurus CUI : CL1906521;
Origin ID : C199621;
chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
- has_target
